Controlled Ovarian Hyperstimulation through Gonadotrophin releasing Hormone Agonist for Patients at Risk of Hyperstimulation Syndrome
|Antonio Maselli1, Martin Wilding1*, Sylvia del Grande1, Stefania Riccio1, Loredana Di Matteo1,2 and Brian Dale1|
|1Centro Fecondazione Assistita, Clinica Villa del Sole, Via Manzoni 15, 80122 Napoli, Italy|
|2Facolta di Medicina e Chirurgia, II Università degli Studi di Napoli, Via Costantinopoli, 16, 80100 Napoli, Italy|
|*Corresponding Author :||Dr. Martin Wilding
Centro Fecondazione Assistita
Clinica Villa del Sole
Via Manzoni 15, 80122 Napoli, Italy
E-mail: [email protected]
|Received December 12, 2011; Accepted February 10, 2012; Published February 20, 2012|
|Citation: Maselli A, Wilding M, Grande SD, Riccio S, Matteo LD, et al. (2012) Controlled Ovarian Hyperstimulation through Gonadotrophin releasing Hormone Agonist for Patients at Risk of Hyperstimulation Syndrome. J Fertiliz in vitro 2:103. doi:10.4172/2165-7491.1000103|
|Copyright: © 2012 Maselli A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background:Patients at high risk of OHSS can experience difficulty in completing an IVF cycle with the administration of gonadotrophins. Here, we test a unique low-dose GnRH agonist protocol.
Methods: 0.1mg triptorlin acetate (decapeptyl) was administered to 18 patients at high risk of OHSS from day 5 of the menstrual cycle. Oocyte retrieval was performed 36 hours after the administration of 10000 IU human chorionic gonadotrophin, when follicles of 18-20mm were observed. Oocytes were fertilised in vitro and embryos transferred on day 3.
Results: Patients produced a mean of 4.1 ± 0.96 oocytes. After ICSI, a mean of 3.0 ± 0.84 embryos were transferred to the uterus. A total of 5 pregnancies were obtained from the 18 cycles. No patients were affected by OHSS.
Conclusions: Low-dose injections of GnRH analogues can cause multiple follicular development, mature oocytes and pregnancies in patients at risk of OHSS. This novel COH protocol appears safe and applicable as a valuable alternative to the natural cycle.